No hepatic veno-occlusive disease was reported. find more Grade II-IV acute GVHD and any grade chronic GVHD occurred in 21.1% and 41.7%, respectively. Conclusion RIC with busulfan and fludarabine is an effective and safe conditioning regimen for adult ALL patients unfit for myeloablation.Background Laryngeal cancer (LC) is one of the common malignant tumors in the head and neck area, and the survival rate for patients is low. Objectives To investigate miR-122a and miR-3195 expressions in LC tissue, their correlations with clinicopathological features, and their impacts on Hep-2 proliferation and apoptosis. Material and methods Thirty LC and 20 peritumoral tissue specimens were analyzed. miR-122a, miR-122a-negative control sequence, miR-3195, and miR-3195-NG sequence were transfected into Hep-2 in the miR-122a-mimics, miR-122a-NG, miR-3195-mimics, and miR-3195-NG groups, respectively. The miR-122a-mimics-non-transfected and miR-3195-mimics-non-transfected groups used non-transfected Hep-2. Results There were lower miR-122a, miR-3195 and occludin protein, and higher TBX1 protein expressions in LC than in the peritumoral tissue; the miR-122a level was associated with clinical stage (all p less then 0.001). Positive correlations between miR-122a and miR-3195, and miR-122a and occludin expressions, and a negative correlation between miR-3195 and TBX1 expressions were observed (r = 0.418, r = 0.541, r = -0.428, all p less then 0.001). The miR-122a and miR-3195 levels in the 2 mimics groups increased respectively compared to their NG and the non-transfected groups. At different time points after 24 h of transfection, the optical density in the 2 mimics groups was lower than in their NG groups. The miR-122a-mimics group had an increased occludin level and the miR-3195-mimics group had a decreased TBX1 level, and both groups had greater apoptosis rates than their NG groups and in the non-transfected groups (all p less then 0.001). Conclusions miR-122a is associated with clinical stage. miR-122a and miR-3195 may act as tumor suppressors and play a role in LC pathogenesis. They can suppress Hep-2 proliferation and promote its apoptosis, probably owing to the upregulation of occludin by miR-122a and suppression of TBX1 by miR-3195.Background Treatment with cyclosporine A (CsA), a calcineurin inhibitor, is effective in children with difficult idiopathic nephrotic syndrome (INS). Prolonged CsA treatment can result in several adverse effects, the most significant being nephrotoxicity (CsAN). The plasma and urine levels of the proteins annexin V (AnV) and uromodulin (UM) were investigated in order to assess their usefulness as indicators of early-stage CsAN. Uromodulin is considered a distal tubular damage marker. Annnexin V is present in the distal tubules. Objectives To measure AnV in children with INS receiving CsA treatment and to assess the usefulness of this biomarker for monitoring CsAN and as an indicator of changes in the distal tubules of the nephron. Material and methods The prospective study included 30 patients with INS and 22 controls. Plasma and urinary AnV levels were measured 3 times before CsA treatment, and after 6 and 12 months of therapy. The AnV levels were compared to those of UM. Results The urinary AnV and UM levels were significantly higher in the INS patients before CsA therapy in comparison to the reference group. A progressive increase of urinary AnV was observed after 6 and 12 months of therapy. Urinary UM only increased after 6 months. No significant correlations were found between plasma and urinary concentrations of the proteins studied. Conclusions The increased urinary excretion of AnV in children with INS receiving CsA treatment may suggest its usefulness as an early marker of subclinical CsAN. Annexin V seems to be a more sensitive indicator of tubular damage in the course of CsA therapy than UM, though large, multicenter studies are needed.Background Kidney transplantation (Tx) is regarded as the optimal treatment method for renal replacement therapy (RRT) for end-stage renal disease (ESRD) patients. Children qualified for Tx should receive the organ as soon as possible in order to improve their chances for healthy development. In our center, RRT for children with ESRD has been conducted for 36 years hemodialysis (HD) since 1982, peritoneal dialysis (PD) since 1992 and the first transplant in 1987. Objectives To analyze the rates of different RRT methods in children with ESRD. Special attention was paid to Tx. Material and methods We compared the rates of RRT methods over 3 subsequent decades (1987-1996, 1997-2006 and 2007-2017). Results In the period analyzed, 153 children aged from 2 weeks to 18 years were dialyzed. The mean age of the start of RRT was 9.4 years. In 80 children (52.2%), first method was HD, while in 73 patients (47.7%) it was PD. In 25 children, the type of dialysis was changed. Kidney transplantation was performed in 40%, 60.34% and 73% of patients dialyzed in the periods 1987-1996, 1997-2006 and 2007-2017, respectively. The average waiting time for a transplant in the abovementioned decades was 2.25 years, 2.65 years and 1.97 years, respectively. Three children underwent transplantation with a family donor; 1 boy received a transplanted kidney and liver. Two children underwent a preemptive transplant from a deceased donor. Conclusions The percentage of children with ESRD treated with Tx continues to increase, but in our assessment, it still remains too low. Among the types of dialysis, PD was much more frequently used, which is consistent with pediatric recommendations. Small number of transplants from a living donor and preemptive transplants indicates the need to promote organ donation in Polish society.Coronavirus disease 2019 (COVID-19) is spreading worldwide, and has been declared as an international public health concern. Patients with lung cancer are highly susceptible to infection compared to healthy individuals because of systemic immunosuppression induced by malignancy and anticancer therapy. Furthermore, patients with cancer demonstrate poorer outcomes following infection. Hence, patients with lung cancer should be considered a priority group for COVID-19 prevention. Furthermore, the routine treatment of patients with cancer has been affected during the COVID-19 pandemic, and patients may not have been able to undergo timely and effective antitumor treatment, thereby indicating a poor prognosis. Here, we provide some suggestions for early identification of COVID-19 and differential diagnosis in patients with lung cancer who have fever and respiratory symptoms. Our medical team also provide clinical recommendations on lung cancer management during the COVID-19 pandemic, for carrying out meticulous and individualized clinical management of lung cancer patients and maximum protection to effectively prevent COVID-19.